Bayer's Lung Cancer Drug Gets Breakthrough Therapy Status in China
Provided by
Dow Jones
By Helena Smolak
Bayer received breakthrough therapy designation for its experimental lung cancer drug from China's Center for Drug Evaluation, accelerating its development and potential access for patients.
The German pharmaceutical and biotechnology company said on Tuesday that it is currently evaluating its targeted therapy in Phase 1 and 2 trials for the treatment of inoperable or metastatic non-small cell lung cancer with activating HER2 mutations.
The drug received breakthrough therapy designation from the U.S. Food and Drug Administration in February.
Write to Helena Smolak at helena.smolak@wsj.com
(END) Dow Jones Newswires
June 11, 2024 04:58 ET (08:58 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
4 Predictions for Stocks and the Economy for the Second Half of 2024
-
What Broadening Rally? AI Stocks Dominate Again In Q2
-
After Earnings, Is Nike Stock a Buy, a Sell, or Fairly Valued?
-
Worst-Performing Stock ETFs of the Quarter
-
Top-Performing Stock ETFs of the Quarter
-
Q2 In Review and Q3 2024 Market Outlook
-
5 Stocks to Buy for 3Q 2024
-
Best- and Worst-Performing Stocks of Q2 2024
-
Industrials: Sector Offers Investment Opportunities as Performance Lags Broader Market
-
Consumer Defensives: Even Amid Macro Pressures, Deals Permeate the Landscape
-
33 Undervalued Stocks
-
Utilities: Can the Stocks Keep the Rally Going?
-
Basic Materials: Following Index Decline, We See Many Long-Term Opportunities
-
Healthcare: Valuations Look Attractive In Most Industries
-
Financial Services: Amid Uncertainties, We See the Most Value In Banks and Credit Services
-
Consumer Cyclicals: Even With Anxiety Over Spending, We See Attractive Valuations